ian Wilmut, the scientist who created Dolly, the world's first mammal cloned from an adult cell has struck a million-dollar deal with a us company to work on human cloning. According to a report in the London Daily Telegraph , Wilmut had agreed to help develop techniques to clone a patient's own cells for transplant, which could provide treatment for a wide range of degenerative diseases.
The project is a collaboration between the Roslin Institute, near Edinburgh, where Dolly was cloned in 1997, and the Californian-based company Geron. Wilmut will receive 83,000 shares of Geron, each worth us $12.
The report said that the new research will have many applications including insulin-producing cells to treat diabetes, nerve cells for stroke, Parkinson's disease and Alzheimer's patients, muscle cells to treat heart attacks and liver cells for the treatment of hepatitis. Producing tissue and cells for transplant will require the cloning of early human embryos, Wilmut said.